Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
9.04 USD | -2.06% | -12.57% | -36.29% |
05-10 | UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating | MT |
05-09 | Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-36.29% | 2.73B | |
+26.37% | 44.96B | |
-1.01% | 42.65B | |
+46.00% | 41.85B | |
-5.31% | 29.04B | |
+9.34% | 26.08B | |
-21.69% | 19.03B | |
+6.23% | 12.75B | |
+26.99% | 12.06B | |
-3.38% | 11.75B |
- Stock Market
- Equities
- FOLD Stock
- News Amicus Therapeutics, Inc.
- Amicus Therapeutics : Arya Sciences Acquisition Corp to Create Genetic Medicine Company Caritas Therapeutics